 |
        |
About ORTHOCON®Founded in 2005, ORTHOCON develops, manufactures, markets, and sells implantable products designed to stop bone bleeding. In 2010, ORTHOCON launched its first commercial product. HEMASORB® Resorbable Hemostatic Bone Putty is a ready-to-use, biocompatible, water resistant, and resorbable putty that is designed to rapidly stop bleeding when applied to damaged or cut bone. ORTHOCON believes HEMASORB has the potential to become a standard of care for the management of surgical bone bleeding. Guided by a seasoned management team comprised of physicians, Ph.D.'s and business leaders, ORTHOCON is positioned to provide safe and effective surgical solutions from which patients will benefit, surgeons will find superior to existing products and administrators will find cost effective. ORTHOCON is privately-held and financed by leading international venture capital investment firms. The company occupies 8,000 square feet at its state-of-the-art facility in Irvington, New York. |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
Canaan Partners Closes $600 Million Fund, Canaan IX
January 9, 2012 - Click to Read More ORTHOCON® Announces Signing of Exclusive, Worldwide License Agreement with Bezwada Biomedical August 31, 2011 - Click to Download |
||
|
||||||
